ReviewFrontiers in immunology2023
Multi-omics in HIV: searching insights to understand immunological non-response in PLHIV.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- HIV immunological nonresponders show low SKAP1 concentration and DNA hypermethylation in the SKAP1 promotor region.AIDS (London, England) · 2026Article
- Intestinal microecology: a crucial factor influencing incomplete immune reconstitution after antiretroviral therapy in people living with HIV-1.Frontiers in public health · 2026Review
- Integrative single-cell transcriptomic analysis reveals immunomodulatory hub genes and candidate compounds for HIV-associated chronic inflammation.Virology journal · 2025Article
- GNLY+CD8+ T cells bridge premature aging and persistent inflammation in people living with HIV.Emerging microbes & infections · 2025Article
- Patterns of immune recovery in people living with HIV who initiated antiretroviral therapy as late presenters.BMC infectious diseases · 2025Article
- Role of Artificial Intelligence and Personalized Medicine in Enhancing HIV Management and Treatment Outcomes.Life (Basel, Switzerland) · 2025Review
- Mortality and immunological indicators of men who have sex with men living with HIV on antiretroviral therapy: a 10-year retrospective cohort study in Southern China.BMC infectious diseases · 2025Article
- How to properly define immunological nonresponse to antiretroviral therapy in people living with HIV? an integrative review.Frontiers in immunology · 2025Review
- Latent reservoirs in memory T cell subsets are linked to poor immune recovery in people living with HIV.Frontiers in immunology · 2025Article
- HIV-Induced Thymic Insufficiency and Aging-Related Immunosenescence on Immune Reconstitution in ART-Treated Patients.Vaccines · 2024Article
- HIV immunological non-responders are characterized by extensive immunosenescence and impaired lymphocyte cytokine production capacity.Frontiers in immunology · 2024Article
- From glycosylation to inflammation: insights from NMR-Derived GlycA and GlycB.Journal of circulating biomarkersReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiretroviral therapy (ART) induces persistent suppression of HIV-1 replication and gradual recovery of T-cell counts, and consequently, morbidity and mortality from HIV-related illnesses have been significantly reduced. However, in approximately 30% of people living with HIV (PLHIV) on ART, CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.